KRAS and cancer: Our findings suggest that therapeutic blockade of PI3K/Akt or mTORC1, but not KRAS, signalling in cancer can induce a switch in secreted exosome subtype, although in some cells, complete mTORC1 inhibition appears to strongly reduce all exosome secretion.